jobs

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Metsera, Inc. - Common Stock (NQ:MTSR)

63.04 -0.69 (-1.08%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 31, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Metsera, Inc. - Common Stock

< Previous 1 2 3 Next >
Is It Time to Dump Your Shares of Pfizer?
Pfizer stock has dropped 50% over the past three years. 
Via The Motley Fool
Topics Intellectual Property
Pfizer Sues Novo Nordisk And Metsera To Block The Proposed $6.5 Billion Deal
Pfizer sued Metsera and Novo Nordisk on Friday to prevent Novo's proposed $6.5 billion takeover of the smaller company. 
Via Investor's Business Daily
Topics Law Enforcement Lawsuit
Viking Therapeutics Stock Powers Toward Best Month Of The Year — Wall Street, Retail Bulls Fired Up On Obesity Drug Promise
Traders on Stocktwits linked Novo Nordisk’s renewed bid for Metsera to competition from Viking’s obesity drug VK2735, fueling further optimism. 
Via Stocktwits
10 Health Care Stocks Whale Activity In Today's Session
 
Via Benzinga
Retail Investors Now Expect Viking Therapeutics To Bag A Deal After Novo Nordisk, Pfizer Engage In A Bidding War For Rival Metsera
Via Stocktwits
Novo Nordisk Submits Revised Bid For Metsera, Enters A Bidding War With Pfizer
Via Stocktwits
Viking Therapeutics Ignites Retail-Trader Frenzy Amid Deal Speculation, Upcoming Trial Catalysts
Via Stocktwits
Novo Nordisk Kicks Off Bloody Battle With Pfizer, Bidding $6.5 Billion On Metsera
Novo Nordisk kicked off a battle with Pfizer on Thursday, making an unsolicited $6.5 billion bid for obesity-focused Metsera. 
Via Investor's Business Daily
Topics Economy Government
12 Health Care Stocks Moving In Thursday's Intraday Session
 
Via Benzinga
Pfizer Blasts Novo Nordisk's $9 Billion Counteroffer For Metsera As 'Reckless'
Novo Nordisk's $9 billion offer for Metsera challenges Pfizer's existing merger deal, prompting sharp criticism and potential legal action. 
Via Benzinga
The market is filled with gapping stocks in Thursday's session.
Today's session on Thursday is marked by notable gaps in various stocks. Stay informed with the gap up and gap down stocks in today's session. 
Via Chartmill
Cardinal Health Posts Upbeat Q1 Results, Joins Guardant Health, Glaukos, C.H. Robinson And Other Big Stocks Moving Higher On Thursday
 
Via Benzinga
Why Alphabet Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
2 High-Yield Stocks With Fresh Catalysts
Income investors can capture yields above 5% from companies executing business transformations. 
Via The Motley Fool
Topics Lawsuit
Google Parent Alphabet Has $754 Million Invested in These 3 Hot Growth Stocks. Here's the 1 Wall Street Likes the Most.
At least one of these stocks owned by Alphabet could be a great pick for aggressive investors. 
Via The Motley Fool
2 Unstoppable Dividend Stocks Yielding More Than 4% That Income-Seeking Investors Will Want to Buy in November and Hold Forever
Both companies are monsters in their industry and are poised to thrive. 
Via The Motley Fool
Topics Government Intellectual Property World Trade
2 Mega-Dividend Stocks With Yields As High As 7%
Dividend stocks with high yields can be great investment opportunities, but those yields can also be red flags. 
Via The Motley Fool
Topics Economy Government Intellectual Property
Down 44%, Should You Buy the Dip on Viking Therapeutics?
The company is readying to take on pharma giants Novo Nordisk and Eli Lilly. 
Via The Motley Fool
Where Will Pfizer Be in 5 Years?
Pfizer is working hard to deal with some big headwinds it has coming up, but in five years, this should all be in the past. 
Via The Motley Fool
Topics Intellectual Property World Trade
Down 50%, Should You Buy the Dip on Pfizer?
Pfizer's stock price is down materially from its 2021 highs, but it is also up notably from its April 2025 lows. 
Via The Motley Fool
Topics Intellectual Property
3 Reasons to Buy Pfizer Stock Now
After years of underperformance, the future is looking brighter for the drugmaker. 
Via The Motley Fool
2 Reliable Dividend Stocks With Yields Above 6% That You Can Buy With $100 in October
You don't need to be rich to put your money to work on Wall Street. 
Via The Motley Fool
Topics Intellectual Property
3 Things You Need to Know if You Buy Pfizer Today
Pfizer has an attractive 7.2% dividend yield, but there are some pros and cons you need to understand before you buy it. 
Via The Motley Fool
Topics Intellectual Property
Got $200? 2 Healthcare Stocks to Buy and Hold Forever
These stocks could see growth take off over the next few years. 
Via The Motley Fool
Metsera Reports Up To 14% Weight Loss In Phase 2b Obesity Trial
Metsera's MET-097i cut weight up to 14% in Phase 2b trials, with manageable side effects, as the company targets a global Phase 3 program in 2025. 
Via Benzinga
Pfizer Just Reminded Investors Why You Should Never Count Its Stock Out
The company recently announced an acquisition that will bolster its growth prospects in the GLP-1 obesity market. 
Via The Motley Fool
3 High-Yield Dividend Stocks to Buy Now for a Lifetime of Passive Income
Right now, these dividend payers are top options for folks who like to set it and forget it. 
Via The Motley Fool
Topics Artificial Intelligence Economy
Down 55%, Should You Buy the Dip on Pfizer?
Pfizer is facing a patent cliff and has a high payout ratio, but it is taking steps to get back on track. 
Via The Motley Fool
Topics Intellectual Property
Is Pfizer Stock a Buy After Its $5 Billion GLP-1 Bet?
The company continues to improve its pipeline. 
Via The Motley Fool
Pfizer is Locking in New Growth Through a New Acquisition
Pfizer is undergoing a new acquisition, exposing it to the weight loss market and additional revenue growth potential, which isn't priced in yet. 
Via MarketBeat
Topics Artificial Intelligence
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

More ways to get to us

Medicine Hat News Twitter Twitter
Medicine Hat News Facebook Facebook
Medicine Hat News Instagram Instagram
Medicine Hat News YouTube YouTube
Medicine Hat News Tumblr Tumblr

About Us

Contact the Medicine Hat News

922 Allowance Ave SE
Medicine Hat, AB T1A 3G7

Office hours: 8:30 a.m.-4:30 p.m. Monday to Friday, closed Saturday Sunday and statutory holidays.

[P] 403.527.1101
[F] 403-527-0737

Print Advertising: 403.528.5659
National Advertising: 403.528.5766
Online Advertising: 403.528.5698
Classifieds: 403.526.7653

© 1996-2024 The Medicine Hat News